After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...
Stephen Abreu has been appointed by the Board as Executive Director. He will lead the organization's overall strategy and ...
Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show ...
Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...
GlobalData on MSN1d
How decentralisation can fill the gaps in Alzheimer’s researchAlzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...
Leading life science and deep tech investors IQ Capital, Cancer Research Horizons, the US National Brain Tumor Society’s Brain Tumor Investment Fund, AIN Ventures and the University of Edinburgh’s ...
On Friday, Biogen Inc (BIIB) stock saw a decline, ending the day at $159.99 which represents a decrease of $-4.90 or -2.97% from the prior close of $164.89. The stock opened at $165.46 and touched a ...
A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback